A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of a sulfonylurea in patients with type 2 diabetes not adequately controlled with sulfonylurea

A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of a sulfonylurea in patients with type 2 diabetes not adequately controlled with sulfonylurea.

Registry ID

EUCTR2007-005881-11

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Sanofi-Aventis Recherche&Développement

Start date

2008-08-15

Last update

2026-08-16

Conditions

• Type II Diabetes

Summary

The primary objective of this study is to assess the effects of AVE0010 on glycemic control in comparison to placebo as an add-on treatment to sulfonylurea, without or with metformin, in terms of absolute HbA1c reduction over a period of 24 weeks in patients with type 2 diabetes.

Locations

• , , Germany
• , , Czechia
• , , Netherlands
• , , Bulgarian Drug Agency

Related clinical trials

• The GRoceries Aimed at Increasing Nutrition Study
• Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
• Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
• Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
• Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.

View on source registry